[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Athletic Greens International\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100626613","a-randomized-triple-blind-placebo-controlled-study-to-evaluate-the-effects-of-a-supplement-on-nutrient-gaps-and-gut-health-among-individuals-utilizing-glp-1-ras-100626613",false,"NCT07437911","A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs","Inclusion Criteria:\n\n* Be male or female\n* Be aged 18-59.\n* Has a BMI between 20-31.9.\n* Anyone currently taking GLP-1 medication at their maintenance dose (week 8+), and without any plans to alter their dosage. This includes: Semaglutide (Ozempic®, Wegovy®, Rybelsus®), Liraglutide (Saxenda®, Victoza®), Dulaglutide (Trulicity®), Exenatide (Byetta®, Bydureon®), Lixisenatide (Adlyxin®)\n* Anyone willing to follow the study protocol, including immediately prior to the all blood tests, duplicating their diet for 72 hours (3 days), refraining from caffeine and exercise for 24 hours, and fasting for 10 hours.\n* Anyone willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial.\n* Anyone willing to avoid introducing any other supplements, medications, or herbal remedies for the duration of this trial.\n* Anyone who is generally healthy - does not live with any diagnosed uncontrolled chronic disease.\n* Has access to a consistent weighing scale for the duration of the study.\n* Resides in the United States.\n\nExclusion Criteria:\n\n* Anyone with a diagnosis of Type I or Type II diabetes.\n* Anyone with a diagnosis of any metabolic health condition, such as hypertension and dyslipidemia.\n* Anyone who has taken any multivitamin\u002Fmultimineral supplements within the past 3 months.\n* Anyone who has taken a probiotic supplement within the past month.\n* Anyone who has regularly consumed (5 days\u002Fweek or more) products that target healthy aging, anti-aging, longevity, gut health, energy, or ingestive behaviour (such as cravings), including resveratrol, quercetin, pterostilbene, coQ10, grapefruit, nicotinamide riboside, prebiotic fiber, green tea, niacin (vitamin B3) within the past 2 months.\n* Anyone who has received an antibiotic, antifungal, antiparasitic, or antiviral treatment within the past 90 days.\n* Anyone who has a known history of severe digestive disorders or metabolic conditions that impact nutrient absorption or metabolism, including acid reflux, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), Crohn's disease, a history of colon resection, gastroparesis, Inborn errors of metabolism (such as PKU), or gastrointestinal tract surgeries.\n* Anyone with any known allergies or hypersensitivities to any supplement product ingredients.\n* Anyone with any chronic health conditions that could impact participation in this study, such as asthma, gout, fibromyalgia, chronic inflammatory conditions (such as Crohn's, Lupus, HIV\u002FAIDS), thyroid conditions, cancer (within the past 5 years), mental health disorders, history of serious illness in the last three months, history of substance abuse, or planned surgery during the study period.\n* Anyone currently pregnant, trying to conceive, or breastfeeding.\n* Anyone who has undergone a change in hormone therapy (including oral contraceptives) within the past 4 weeks, or is unwilling to maintain their current hormone therapy\u002Foral contraceptive use throughout the course of the study.\n* Anyone who consumes more than 2 standard alcoholic drinks per day or more than 10 drinks per week, or has within the past 6 months.\n* Anyone who is currently a smoker or has been a smoker within the past month.\n* Anyone who follows a specific exclusion diet, including vegan, vegetarian, carnivore, paleo, atkins, or ketogenic.","ALL","18 Years","59 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a triple-blind, placebo-controlled, randomized controlled trial of 120 adults that will evaluate the impact of a novel nutritional supplement on improving nutrient gaps and changing nutrient status and the gut microbiome among glucagon-like peptide-1 receptor agonist (GLP-1 RA) users.",[26,27,28,29],"Nutrition Intake","Nutrition Status","Gastrointestinal Microbiome","GLP-1","RECRUITING","2026-02-24",{"date":33,"type":34},"2026-02-27","ACTUAL",{"date":36,"type":20},"2026-02",{"date":38,"type":20},"2026-08",{"name":40,"class":41},"Athletic Greens International","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":15,"minAge":51,"maxAge":17,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100616886","sleep-and-morning-wellbeing-study-100616886","NCT07311434","Sleep and Morning Wellbeing Study","Evaluation of Perceived Outcomes With AGZ: A Randomized, Controlled, Consumer Perception Study","Inclusion Criteria:\n\n* Male or female.\n* Age 25-59 years.\n* BMI ≥18.5 and ≤29.9 kg\u002Fm².\n* Currently experiencing issues with sleep quality, falling asleep, staying asleep, or waking during the night.\n* RU-SATED score ≤17.\n* Willing and able to follow the study protocol.\n* Willing to discontinue any other supplements (including nootropics, adaptogens, calming herbs), medications, herbal remedies, or over-the-counter sleep medications (e.g., zolpidem, diphenhydramine, Benadryl, ZzzQuil, Unisom, magnesium or melatonin products) used to assist with sleep during the study.\n* Agree to limit alcohol intake within approximately 4 hours of bedtime throughout participation.\n* Agree to limit caffeine intake to ≤400 mg\u002Fday (about 3-4 cups of coffee) and avoid ingestion of caffeine-containing products after 2:00 PM during the study period.\n* Generally healthy and not living with any uncontrolled chronic disease.\n* Resides in the United States.\n* Willing to discontinue any restricted products and adhere to all required study assessments.\n\nExclusion Criteria:\n\n* Diagnosed chronic sleep conditions (e.g., insomnia, narcolepsy, REM Behavior Disorder, moderate to severe restless leg syndrome, sleep apnea).\n* Current use of sleep-tracking technology (e.g., wrist-worn trackers, rings, smartphone apps) that could influence sleep behavior or perception.\n\nWomen currently undergoing perimenopause or experiencing vasomotor symptoms (e.g., night sweats).\n\n* Use of hormone therapy (estrogen, progesterone, phytoestrogens) within the last 3 months.\n* Diagnosed psychiatric disorders including major depressive disorder with acute symptoms, bipolar disorder, generalized anxiety disorder with active symptoms, and PTSD with frequent nightmares.\n* Diagnosed neurodegenerative or chronic pain disorders, including Parkinson's disease, Alzheimer's disease, or uncontrolled fibromyalgia.\n* Regular prescribed stimulant use (e.g., amphetamines such as Adderall\u002FVyvanse; methylphenidate such as Ritalin\u002FConcerta; modafinil\u002Farmodafinil).\n* Current use of CNS-activating antidepressants (bupropion, fluoxetine, venlafaxine, sertraline).\n* Current or recent use of cannabis or THC-containing products (recreational or medicinal marijuana, CBD with measurable THC, synthetic cannabinoids) within the past 30 days.\n* Employment in jobs disrupting nighttime sleep (e.g., night shift, rotating shift, excessive travel).\n* Current use of prescription sleep aids.\n* Introduction of any new sleep-related supplements, medications, herbal remedies, or melatonin products during the study.\n* Use of any prescription or OTC products with sedative properties (e.g., melatonin, diphenhydramine, doxylamine, valerian, ZzzQuil, Advil PM) within 4 weeks prior to enrollment or habitual use ≥3 times per week prior to enrollment unless investigator-approved.\n* Allergy or sensitivity to any study product ingredients.\n* Pregnant, breastfeeding, or trying to conceive during the study period.\n* History of substance abuse.\n* Heavy alcohol use (≥8 drinks\u002Fweek for women or ≥15 drinks\u002Fweek for men).\n* Participation in another research study now or within the next 7 weeks.\n* Any condition or behavior that, in the investigator's judgment, may interfere with study participation or data integrity.",true,"22 Years",{"count":53,"type":20},300,[23],"The study will be a prospective randomized, controlled clinical study. There will be interventional treatment for a total of 30 days. The subjects will complete questionnaires throughout the study at pre-specified timepoints.",[57,58,59,60],"Sleep","Relaxation","Stress","Daytime Sleepiness","2026-02-10",{"date":63,"type":34},"2026-02-11",{"date":65,"type":34},"2026-01-20",{"date":67,"type":20},"2026-06-01",{"name":40,"class":41},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":50,"sex":15,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":42},"100619487","the-effects-of-a-nutritional-supplement-on-sleep-quality-100619487","NCT07345260","The Effects of a Nutritional Supplement on Sleep Quality","Inclusion Criteria:\n\n1. Be male or female\n2. Be aged 35-65.\n3. Body Mass Index: ≥18.5 and ≤29.9 kg\u002Fm2\n4. Anyone currently experiencing issues with falling asleep, staying asleep, or waking up during the night\n5. Score of 7 or less on the RU-SATED validated sleep questionnaire.\n6. Anyone willing to follow the study protocol.\n7. Anyone willing to discontinue any other supplements (nootroptics, adaptogens, calming herbs), medications, herbal remedies, over the counter sleep medications \\[e.g., zolipidem, diphenhydramine (Benadryl or unisom), magnesium or melatonin products\\] used to assist with sleep for the duration of the study.\n8. Agree to limit alcohol intake within \\~4 hours of bedtime\n9. Agree to limit caffeine intake to ≤ 400 mg\u002Fday (\\~3-4 cups of coffee) or ingestion of caffeine-containing products after 2:00 PM during the study period.\n10. Anyone who is generally healthy - does not live with any uncontrolled chronic disease.\n11. Resides in the United States.\n\nExclusion Criteria:\n\n1. Anyone with a diagnosed chronic sleep condition, including but not limited to insomnia, narcolepsy, REM Behavior Disorder, moderate to severe restless leg syndrome (RLS), or sleep apnea.\n2. Women currently undergoing perimenopause or experiencing vasomotor symptoms such as night sweats.\n3. Use of hormone therapy (including estrogen, progesterone, or phytoestrogens) within the last 3 months.\n4. Anyone with diagnosed psychiatric disorders including major depressive disorder with acute symptoms, Bipolar disorder, Generalized anxiety disorder with active symptoms, PTSD with frequent nightmares\n5. Anyone with diagnosed neurogenitive diseases or chronic pain disorders including Parkinson's disease, Alzheimer's disease, or uncontrolled fibromyalgia\n6. Anyone who regularly consumes prescribed stimulant medications including Amphetamines (e.g., Adderall, Vyvanse), Methylphenidate (e.g., Ritalin, Concerta), and Modafinil \u002F Armodafinil\n7. Anyone currently on CNS activating anti-depressants including Bupropion (Wellbutrin), Fluoxetine, Venlafaxine (Effexor), Sertraline (Zoloft).\n8. Current or recent use of cannabis or THC-containing products, including recreational or medicinal marijuana, CBD products with measurable THC content, or synthetic cannabinoids, within the past 30 days.\n9. Anyone with a job that disrupts their nighttime sleep (e.g., excessive travel, night\u002F3rd shift workers).\n10. Anyone unwilling to wear the Oura ring device for the duration of the trial or unwilling to open the Oura application at least three times each week during the trial for data to sync to the cloud\n11. Anyone currently taking a prescription sleep aid.\n12. Anyone who introduces any new supplements, medications, herbal remedies, or melatonin products used to assist with sleep for the duration of the study.\n13. Anyone with any allergies or sensitivities to any of the study product ingredients.\n14. Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).\n15. Anyone with a history of substance abuse.\n16. Anyone who drinks heavily (i.e., 8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).\n17. Currently partaking in another research study or will be partaking in any other research study for the next 7 weeks, or at any point during this study's duration.","35 Years","65 Years",{"count":78,"type":20},140,[23],"This study is a randomized, double-blind, placebo-controlled study of N=140 adult men and women with sub-clinical sleep issues. This study to assess the effect of a novel dietary supplement on sleep related outcomes.",[57,82],"Sleep Quality","2026-02-09",{"date":61,"type":34},{"date":86,"type":34},"2026-01-02",{"date":88,"type":20},"2026-05-30",{"name":40,"class":41},""]